Extended Data Fig. 8: Additional analyses of META-55 and META-16 in prostate cancer metastasis.

a, Scaled expression (DESeq2 normalized values) of META-55 in single-cell UMAP projections of primary tumors and bone metastases (see Fig. 7c, d). Shown is the correlation between META-55 expression at the single-cell level with MYC pathway activity (Spearman’s rank correlation rho and p-values). b, c, Heatmap representation of single-sample GSEA enrichment of the META-16 (b) and META-55 (c) gene signatures in primary tumors from TCGA (n = 497) and metastases from SU2C (n = 270) (Supplementary Table 3). Colors correspond to NES. d, e, Violin plots depicting the distribution of the NESs (y-axis) which reflect activity levels of META-16 (d) and META-55 (e) in primary tumors from TCGA (n = 497) compared with metastases from SU2C (n = 270). The p-value was estimated using two-sample one-tailed Welch t-test. In inset box-plots, boxes show the 25th–75th percentile, center-lines show the median, and whiskers show the minimum–maximum values. f, g, Heatmap representation of expression levels of META genes (as indicated) in each of the individual samples from the TCGA (n = 497) and SU2C (n = 270) cohorts. Gleason scores are shown for the primary tumors; metastases include all metastases in the SU2C cohort. Shown are row-scaled expression values (color). Panel f shows the 10 genes from the META-16 signature that do not co-reside with MYC on chromosome 8q, indicated as META-10. Panel g shows the META-55 genes.